Summit Global Investments’s Pacira BioSciences PCRX Stock Holding History

Summit Global Investments’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,044	Closed	-$322K	–	585
2023 Q2	$322K	Buy	+8,044	New	+$333K	0.02%	410
2022 Q4	–	Sell	-20,900	Closed	-$1.11M	–	481
2022 Q3	$1.11M	Buy	20,900 +4,500	+27%	+$250K	0.1%	190
2022 Q2	$956K	Buy	16,400 +1,300	+9%	+$85.2K	0.08%	223
2022 Q1	$1.15M	Sell	15,100 -15,800	-51%	-$1.05M	0.08%	216
2021 Q4	$1.86M	Buy	30,900 +12,800	+71%	+$706K	0.12%	153
2021 Q3	$1.01M	Buy	+18,100	New	+$1.04M	0.08%	197

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Summit Global Investments's PCRX Position: Q3 2023 in Review

Summit Global Investments sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 8,044 shares — an estimated $322K sold.

Summit Global Investments first reported a position in PCRX in Q3 2021 and held it in 6 quarters. The position peaked at $1.86M in Q4 2021. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

Summit Global Investments reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
Summit Global Investments sold 8,044 Pacira BioSciences shares in Q3 2023, an estimated $322K.
Summit Global Investments first reported a position in Pacira BioSciences in Q3 2021 and held it in 6 quarters.
Summit Global Investments's Pacira BioSciences position peaked at $1.86M in Q4 2021.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on Summit Global Investments's 13F filing for Q3 2023, filed 16 Oct 2023.